Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy

• Published in: Journal of controlled release 2024-03, Vol.367, p.13-26
• Main Authors: Zhang, Xiuli, Wei, Mingjing, Zhang, Zhigang, Zeng, Yarong, Zou, Feihong, Zhang, Sibo, Wang, Zhiping, Chen, Fentian, Xiong, Hualong, Li, Yufang, Zhou, Lizhi, Li, Tingting, Zheng, Qingbing, Yu, Hai, Zhang, Jun, Gu, Ying, Zhao, Qinjian, Li, Shaowei, Xia, Ningshao
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Animals; Antibodies, Viral; Antigens; Bisphosphonates; Durapatite; Humans; Immunotherapy; Manganese; Mice; Neoplasms; Risedronate; Risedronic Acid; Spike Glycoprotein, Coronavirus; Tumor immunotherapy; Vaccine adjuvant; Vaccines, Subunit
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2024.01.033

The cGAS-STING pathway and the Mevalonate Pathway are druggable targets for vaccine adjuvant discovery. Manganese (Mn) and bisphosphonates are known to exert adjuvant effects by targeting these two pathways, respectively. This study found the synergistic potential of the two pathways in enhancing immune response. Risedronate (Ris) significantly amplified the Mn adjuvant early antibody response by 166-fold and fortified its cellular immunity. However, direct combination of Mn2+ and Ris resulted in increased adjuvant toxicity (40% mouse mortality). By the combination of doping property of hydroxyapatite (HA) and its high affinity for Ris, we designed Ris-functionalized Mn-HA micro-nanoparticles as an organic-inorganic hybrid adjuvant, named MnHARis. MnHARis alleviated adjuvant toxicity (100% vs. 60% survival rate) and exhibited good long-term stability. When formulated with the varicella-zoster virus glycoprotein E (gE) antigen, MnHARis triggered a 274.3-fold increase in IgG titers and a 61.3-fold surge in neutralization titers while maintaining a better long-term humoral immunity compared to the aluminum adjuvant. Its efficacy spanned other antigens, including ovalbumin, HPV18 VLP, and SARS-CoV-2 spike protein. Notably, the cellular immunity elicited by the group of gE + MnHARis was comparable to the renowned Shingrix®. Moreover, intratumoral co-administration with an anti-trophoblast cell surface antigen 2 nanobody revealed synergistic antitumor capabilities. These findings underscore the potential of MnHARis as a potent adjuvant for augmenting vaccine immune responses and improving cancer immunotherapy outcomes. Risedronate (Ris)-functionalized manganese (Mn2+)-HA adjuvant was designed, named MnHARis. The Mn2+ and Ris co-dopion successfully transformed HA crystalline rodlike precipitation into Mn/CaRis amorphous precipitates. MnHARis enhanced antigen presenting cells (APCs) activation and induced robust humoral and cellular immunity in subunit vaccines. Moreover, MnHARis demonstrated a synergistic anti-cancer effect when co-administered intratumorally with nanobody. [Display omitted]